Global Inflammatory Bowel Disease (IBD) Therapeutics Market to Reach $32.8 Billion by 2030
The global market for Inflammatory Bowel Disease (IBD) Therapeutics estimated at US$23.2 Billion in the year 2022, is projected to reach a revised size of US$32.8 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2022-2030. TNF inhibitors, one of the segments analyzed in the report, is projected to record 5.5% CAGR and reach US$14 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Anti-integrin segment is readjusted to a revised 4.2% CAGR for the next 8-year period.The U.S. Market is Estimated at $6.3 Billion, While China is Forecast to Grow at 8.7% CAGR
The Inflammatory Bowel Disease (IBD) Therapeutics market in the U.S. is estimated at US$6.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$7.6 Billion by the year 2030 trailing a CAGR of 8.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.4% and 3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.Select Competitors (Total 69 Featured) -
- 4SC AG
- Abbott Nutrition
- AbbVie, Inc.
- Ablynx NV
- Active Biotech AB
- Alfasigma S.p.A.
- Allergan PLC
- Allergan PLC
- Amgen, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Athersys, Inc.
- Atlantic Healthcare plc
- Avaxia Biologics, Inc.
- Biosafe Systems, LLC
- Boehringer Ingelheim GmbH
- Cadila Healthcare Ltd.
- Celgene Corporation
- Celltrion, Inc.
- Cipla Ltd.
- Coherus Biosciences, Inc.
- Cosmo Pharmaceuticals NV
- Dr. Falk Pharma GmbH
- EA Pharma Co., Ltd.
- Eddingpharm
- EPIRUS Biopharmaceuticals, Inc.
- F. Hoffmann-La Roche AG
- F. Hoffmann-La Roche AG
- Galapagos NV
- Giaconda Ltd.
- Google LLC
- Immunic, Inc.
- InDex Pharmaceuticals Holding AB
- Infinity Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Janssen Biotech, Inc.
- Johnson & Johnson
- Kissei Pharmaceutical Co., Ltd.
- LG Sciences
- Lupin Ltd.
- Mochida Pharmaceutical Co., Ltd.
- Mylan Pharmaceutical Pvt. Ltd.
- Neovacs SA
- Nogra Pharma Limited
- NovaMedica LLC
- Novartis International AG
- Osiris Therapeutics, Inc.
- Otsuka Pharmaceutical Co., Ltd.
- PAR Pharmaceutical Companies, Inc.
- PendoPharm, Inc.
- Perrigo Company PLC
- Pfenex, Inc.
- Pfizer, Inc.
- Pharmascience Inc.
- Pluristem Therapeutics, Inc.
- Qu Biologics Inc.
- Quest Diagnostics, Inc.
- RedHill Biopharma Ltd.
- Reliance Life Sciences
- Salix Pharmaceuticals, Inc.
- Sandoz International GmbH
- Sanofi
- Sequella, Inc.
- Soligenix, Inc.
- Takeda Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Toray Industries, Inc.
- Torrent Pharmaceuticals Ltd.
- UCB SA
- Zeria Pharmaceutical Co., Ltd.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4SC AG
- Abbott Nutrition
- AbbVie, Inc.
- Ablynx NV
- Active Biotech AB
- Alfasigma S.p.A.
- Allergan PLC
- Allergan PLC
- Amgen, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Athersys, Inc.
- Atlantic Healthcare plc
- Avaxia Biologics, Inc.
- Biosafe Systems, LLC
- Boehringer Ingelheim GmbH
- Cadila Healthcare Ltd.
- Celgene Corporation
- Celltrion, Inc.
- Cipla Ltd.
- Coherus Biosciences, Inc.
- Cosmo Pharmaceuticals NV
- Dr. Falk Pharma GmbH
- EA Pharma Co., Ltd.
- Eddingpharm
- EPIRUS Biopharmaceuticals, Inc.
- F. Hoffmann-La Roche AG
- F. Hoffmann-La Roche AG
- Galapagos NV
- Giaconda Ltd.
- Google LLC
- Immunic, Inc.
- InDex Pharmaceuticals Holding AB
- Infinity Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Janssen Biotech, Inc.
- Johnson & Johnson
- Kissei Pharmaceutical Co., Ltd.
- LG Sciences
- Lupin Ltd.
- Mochida Pharmaceutical Co., Ltd.
- Mylan Pharmaceutical Pvt. Ltd.
- Neovacs SA
- Nogra Pharma Limited
- NovaMedica LLC
- Novartis International AG
- Osiris Therapeutics, Inc.
- Otsuka Pharmaceutical Co., Ltd.
- PAR Pharmaceutical Companies, Inc.
- PendoPharm, Inc.
- Perrigo Company PLC
- Pfenex, Inc.
- Pfizer, Inc.
- Pharmascience Inc.
- Pluristem Therapeutics, Inc.
- Qu Biologics Inc.
- Quest Diagnostics, Inc.
- RedHill Biopharma Ltd.
- Reliance Life Sciences
- Salix Pharmaceuticals, Inc.
- Sandoz International GmbH
- Sanofi
- Sequella, Inc.
- Soligenix, Inc.
- Takeda Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Toray Industries, Inc.
- Torrent Pharmaceuticals Ltd.
- UCB SA
- Zeria Pharmaceutical Co., Ltd.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 146 |
Published | May 2024 |
Forecast Period | 2020 - 2027 |
Estimated Market Value ( USD | $ 20.6 Billion |
Forecasted Market Value ( USD | $ 27.9 Billion |
Compound Annual Growth Rate | 4.4% |
Regions Covered | Global |